A higher proportion of drug-naive type 2 diabetes patients achieved blood glucose levels lower than 7% with once-daily lixisenatide for 12 weeks compared with those who received placebo treatment, researchers reported in Diabetes Care. Lixisenatide-treated patients also had bigger drops in two-hour postprandial glucose levels than those in the placebo group, researchers noted.

Related Summaries